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Abstract Intravenous tissue plasminogen activator is the
only proven therapy for acute ischemic stroke. Not enough
patients are eligible for treatment and additional new
therapies are needed. Recently, laser technology has been
applied to acute ischemic stroke. This noninvasive technique
uses near-infrared wavelengths applied to the scalp within
24 h of symptom onset. The mechanism is incompletely
understood but may involve increased mitochondrial aden-
osine triphosphate production. Animal models demonstrated
safety and efficacy warranting randomized controlled trials
in humans. NEST-1 (phase 2) and NEST-2 (phase 3)
confirmed the safety of transcranial laser therapy, although
efficacy was not found in NEST-2. Pooled analysis of NEST-
1 and NEST-2 revealed a significantly improved success rate
in patients treated with laser therapy. Further phase 3 testing
is planned and may create a new paradigm for the treatment
of acute ischemic stroke.
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NEST-1 NeuroThera Effectiveness and Safety Trial-1
NEST-2 NeuroThera Effectiveness and Safety Trial-2
NEST-3 NeuroThera Effectiveness and Safety Trial-3
NIHSS National Institutes of Health Stroke Scale
NINDS National Institute of Neurological
Disorders and Stroke
Introduction
Stroke affects nearly three quarters of a million people each
year in the United States, of which more than three quarters
are ischemic [1]. It is the leading cause of adult disability
and the third most common cause of death in industrialized
nations [2]. Despite its prevalence, the only proven
treatment for acute ischemic stroke is intravenous tissue
plasminogen activator (tPA) [3], and although approved in
1995, frustratingly few patients receive therapy [4, 5].
There are several reasons for this. Initially, neurologists and
emergency medicine physicians were tentative to adminis-
ter tPA because of the perceived risk of causing symptom-
atic intracranial hemorrhage (sICH). Data revealing an
extremely low incidence of sICH addressed many of these
concerns [6], although skepticism still exists in the
emergency medicine community [7]. Nonetheless, the
single largest factor currently limiting tPA use is that, per
the NINDS study protocol, it must be administered within
3 h of symptom onset [3, 8]. The vast majority of stroke
patients are not evaluated in this limited time window and
although recent literature supports a modest benefit at 4.5 h
from symptom onset [9, 10], under 5% of stroke patients
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DOI 10.1007/s11886-009-0071-3currently receive tPA [4, 5]. Thus, there is a need for new
therapies that can extend the treatment window.
History
Interactions between light and biology have been recognized
since the concept of photosynthesis originated in the 17th
century. Priestley, among others, elucidated the influence of
sunlight on plants [11], and by the 1770s the basic reaction
incorporating water and carbon dioxide uptake was outlined.
Radiation remained poorly understood until the 1900s when
Albert Einstein published his groundbreaking paper on
photoelectric effects and concepts of absorption, spontaneous
emission, and stimulated emission of electromagnetic radia-
tion [12]. Five decades later the term “laser” (light
amplification by stimulated emission of radiation) was
coined and shortly thereafter the first human-made laser
was created in 1960 [13].
We now understand that photobiological reactions such
as photosynthesis entail the absorption of a specific
wavelength of light by a specific molecule. These mole-
cules, or photoreceptors, become electronically excited by
absorbing light and subsequently participate in a metabolic
reaction unrelated to the original light response. Thus, a
laser is simply a tool that uses a light source to excite these
molecules; however, the biological effects of any laser are
wavelength specific when not simply used for tissue
destruction.
Since inception, laser technology has been applied to a
broad spectrum of industries and professions, but some of
the most meaningful applications have been in medicine.
The process began in the 1960s but lasers have infiltrated
many fields of medicine. Dermatology, ophthalmology,
dentistry, otolaryngology, cardiology, and neurology are
only a few of the fields that have benefitted, and in some
cases lasers have revolutionized the way we treat patients
[14–16]. However, until now lasers’ medical applications
have been confined to their ability to selectively ablate
tissue.
Mechanism
Perhaps the most obvious question with transcranial laser
therapy (TLT) is regarding the mechanism of action. It is
known how lasers can cut or cauterize, but how a laser
applied to the scalp during an ischemic stroke can improve
outcomes is more difficult to comprehend.
Several postulated mechanisms seem unlikely. Heat
production, although closely associated with lasers, did
not appreciably elevate brain temperature in preclinical
studies, suggesting that photothermal effects do not play a
role [17•]. Hemodynamic effects (ie, recanalization and
augmented collateral blood flow) are similarly unlikely
because the interval from symptom onset to treatment
extends to 24 h. This is much longer than with intravenous
tPA in which recanalization does not improve outcomes
when administered even 6 h after symptom onset [18–20].
Furthermore, final infarct volumes were not different
between treated and untreated rat models [21].
The most understood mechanism of action involves
the relationship between lasers and cytochrome c
oxidase. The cytochrome c oxidase enzyme complex
contains two copper centers, the first of which contains a
broad wavelength absorption peak when oxidized. Cyto-
chrome c oxidase is located in the inner mitochondrial
membrane and plays a central role in eukaryotic cells. As
a terminal enzyme in the respiratory chain, it delivers
protons across the inner mitochondrial membrane and
enables the formation of adenosine triphosphate (ATP)
by oxidative phosphorylation [22].
For several years, enhanced mitochondrial function
with subsequent preservation of the ischemic penumbra
and improved outcomes has been the hypothesized
mechanism. Only recently has this been demonstrated
using an in vivo model. Lapchak and De Taboada [23]
were the first to demonstrate that TLT substantially
increased cortical ATP production in an embolic stroke
model. This same model was used previously to establish
that TLT can improve clinical rating scores in rabbits and
was similar to the model used to provide preliminary data
for the NEST-1 and NEST-2 trials. After establishing
decreased cortical ATP after embolization, consistent with
the hypothesis of energy depletion after an ischemic event,
laser therapy was found to attenuate embolization-induced
decreases in cortical ATP content (P<0.05). TLT did not
completely normalize cortical ATP content but it increased
overall ATP content by 41%. The authors hypothesized that
this amount should be sufficient to improve or maintain
mitochondrial function, improve neuronal survival, and
produce behavioral improvement [23].
Neurogenesis or central nervous system (CNS) plasticity
may be an additional mechanism of action contributing
toward improved outcomes. Scientific dogma since the time
of Cajal has held that neurogenesis does not occur in
humans, but new research is challenging this concept [24].
Noting that improvement in neurologic outcome may not
be evident for 2–4 weeks in the post-stroke rat model, it has
been postulated that such delayed benefits may be due, in
part, from induction of neurogenesis and migration of
neurons [25]. This is supported by the absence of a
reduction in lesion volume in TLT-treated rats and a
significantly elevated number of newly formed neuronal
cells in the ipsilateral subventricular zone. The presence of
a large number of cells that positively react to doublecortin
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further suggests that increased numbers of cells migrating
to the infarcted area contribute to the improved functional
performance of the laser-treated rats. CNS insults trigger an
increase in progenitor cell proliferation and migration to the
damaged areas; infrared laser energy appears to further
augment this process [21].
Mechanisms such as apoptosis have also been implicated.
Carnevalli et al. [26] investigated the effects of laser therapy
on the mitochondria, nucleus, and cytoskeleton by using
specific fluorescent probes. Treated cells showed increased
levels of cellular division, which was assessed by analyzing
the cytoskeleton and the chromosomes. Moreover, cells
maintained with nutritional deficiencies demonstrated mem-
brane and genetic material that was more preserved
compared with the controls. Therefore, TLT may prevent
apoptosis and improve outcomes by exerting a neuro-
protective effect, although these exact mechanisms are
poorly understood [26].
Various ischemic models including traumatic brain
injury, cardiac muscle ischemia, and skeletal muscle
ischemia have revealed profound protective effects of laser
therapy. Additional mechanisms thought to factor into
benefits of laser therapy are increases in total antioxidants,
angiogenesis, heat shock proteins, inhibition of nitric oxide
synthase, and changes in cerebral microcirculation [27].
The precise mechanisms and cascades are not well defined,
but it seems likely that many factors are intertwined and
contribute toward the overall beneficial effects.
Animal Models
Applying laser technology to acute ischemic strokes
began with animal models. In 2004, Lapchak et al. [28]
used the rabbit small clot embolic stroke model and
applied a gallium-arsenic diode near-infrared laser within
6 h of symptom onset. Significant and sustained improve-
ment was demonstrated in behavioral function measured
24 h after treatment and again at 21 days from stroke onset
[29]. Similar studies confirmed this beneficial effect
despite using a rodent and a different model of inducing
strokes (rat middle cerebral artery occlusion) [21]. There
were differences in the treatment times for which TLT was
effective, but both models resulted in statistically signi-
ficant behavioral improvement that warranted human
trials.
Clinical Trials
The NEST-1 was a prospective, multicenter, international,
double-blind, randomized, placebo-controlled trial. The
principal goals were to examine the safety and efficacy of
TLT administered within 24 h of symptom onset. The
NeuroThera Laser System (Photothera, Carlsbad, CA) is a
noninvasive tool using the near-infrared portion of the
electromagnetic spectrum with a laser wavelength that is
invisible to the naked eye (808 nm). These low-energy
(10-mW/cm²) lasers were applied at 20 predetermined
locations on the scalp with 2 min of irradiation at each
site. The treatment protocol lasted over 1 h and was
applied consistently and independent of the vascular
occlusion site. The NIHSS score, collapsed into a binary
outcome, was prospectively identified as the primary end
point; success occurred as a 90-day NIHSS score 0 to 1
or as a decrease in NIHSS score of ≥9p o i n t sf r o m
baseline to 90 days. Secondary outcome measures
included the modified Rankin Scale (mRS), Barthel
Index, and Glasgow Outcome Scale.
A total of 120 patients were randomized in a 2:1 ratio.
Seventy-nine patients received active therapy at a median of
16 h from stroke onset, resulting in 70% of TLT-treated
patients achieving a positive binary NIHSS outcome
compared with 51% of the control group (P=0.035). These
results were further confirmed after controlling for age, sex,
time to treatment, baseline severity, and previous stroke.
Among TLT-treated patients, 38% achieved a final NIHSS
score of 0 to 1 and improved by ≥9 points compared with
29% of placebo-treated patients. Secondary outcome
measures also revealed that patients who received active
treatment had improved outcomes [30•].
The encouraging phase 2 findings served as a basis for
NEST-2, a phase 3 trial. This was a prospective, double-
blind, randomized, placebo-controlled study that enrolled
660 patients. Inclusion criteria specified patients between
40 and 90 years old, prestroke mRS less than 3, baseline
NIHSS score between 7 and 22, clinical diagnosis of
ischemic stroke within 24 h but not treated with tPA, and no
evidence of intracranial hemorrhage. Patients were random-
ized in a 1:1 ratio to receive TLTor placebo, and all patients
underwent the identical procedure used in NEST-1. Unlike
in NEST-1, the primary efficacy outcome measure was the
90-day dichotomous mRS, with success defined as a score
of 0 to 2 or failure from 3 to 6.
Of the 660 patients, 331 received TLT and 327 received
placebo therapy. In the TLT group, 120 (36.3%) achieved
successful outcomes versus 101 (30.9%) in the control group
(P=0.094). Outcomes showed a trend toward better out-
comes with TLT, but ultimately these failed to reach
statistical significance (P<0.05). Furthermore, subset analy-
sis did not indicate that there was a time-to-treatment effect
within 24 h after symptom onset.
Although we do not have prestroke mRS data from the
two trials to compare the degree of disability upon entrance
to the study, the initial NIHSS scores suggest that patients
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There was a significant difference in the initial NIHSS
scores between NEST-1 (mean NIHSS, 12.2; SD, 3.9) and
NEST-2 (mean NIHSS, 13.1; SD, 4.6).
On post hoc analysis, after those with the most severe
strokes (NIHSS, 16–22) were excluded, a statistically
significant benefit was found. For these remaining 434
patients, the dichotomous mRS success rate of TLT showed
an absolute improvement rate of 9.7% (51.6% TLT vs
41.9% sham) [17•]. Post hoc analysis must be viewed with
skepticism, but TLT may require identification of the
optimal patient group to statistically prove its benefits.
When explaining why NEST-2 was unsuccessful in reach-
ing statistical significance, the authors likened it to the
obstacles encountered when developing tPA.
Several large randomized studies with intravenous tPA
failed to achieve statistical significance despite highly
suggestive trends toward efficacy [18, 19, 31]. Only after
a specific treatment population and treatment time window
were identified was the benefit of tPA clearly established.
The fine-tuning process for tPA lasted many years, but the
strong trend of good clinical outcomes combined with an
excellent safety profile has fostered optimism the wait will
be far shorter for TLT.
Pooled Analysis
To further analyze the two trials, we performed a
retrospective analysis of prospectively collected data. Just
as in NEST-2, binary mRS 90-day end point with success
(mRS, 0–2) and failure (mRS, 3–6) was the primary
efficacy outcome measure used. The null hypothesis that
improved outcomes were not different between TLT and
sham was tested by using logistic regression with two
prespecified covariates (baseline stroke severity and time
from stroke onset to randomization). Combining patients
from the two studies provided 778 patients (120 from
NEST-1, 658 from NEST-2) and the success rate in the TLT
group was strongly significant compared with the sham
group (P=0.003; OR, 1.67; 95% CI, 1.19–2.35).
Safety
Although NEST-2 did not reach significance in its primary
efficacy outcome measure, it did suggest that TLT was
extremely safe. NEST-2 included a broad range of stroke
patients regarding baseline severity, prestroke disability,
and time to treatment and demonstrated that mortality rates,
serious adverse event (SAE) rates, and adverse events were
virtually identical. The TLT group had 58 (17.5%) deaths
and 125 (37.8%) SAEs compared with 57 (17.4%) deaths
and 137 (41.8%) SAEs in the placebo group. No SAEs
were directly attributable to TLT. Hemorrhagic transforma-
tion at day 5 occurred in 49 (14.8%) in the TLT group and
56 (17.1%) in the placebo group [17•]. No differences in
safety outcomes were found between the groups confirming
the safety analysis of previous studies [30•].
Future Studies
The future of TLT requires a third randomized double-blind
prospective study (NEST-3). Based on experience from
NEST-1 and NEST-2, the protocol for NEST-3 will likely
alter inclusion and exclusion criteria (baseline mRS,
baseline NIHSS) to identify those who will benefit the
most. Simultaneously, the combination of TLT and throm-
bolytics is being tested in a separate study. A recently
completed trial using rabbits and an embolic model tested
TLT applied after administration of intravenous tPA. The
results showed that this combination did not adversely
affect hemorrhage rate, volume, or survival compared with
tPA alone [32•]. It was only intended to test safety, but
theoretically the different mechanisms of action of TLT and
tPA could synergistically treat strokes. Based on this study
a clinical trial testing TLT plus tPA was recommended and
is on the horizon.
Conclusions
The application of TLT in acute ischemic stroke is in its
early stages. Compelling evidence that it is safe and
effective has led to the tantalizing possibility of signifi-
cantly expanding the treatment window and changing the
paradigm for stroke treatment. Confirmatory studies are
needed, and to this end, protocols are currently being
developed that identify the optimal laser settings, patient
population, and time to treatment. Projecting further, it will
be fascinating to see if TLT and tPA can be used in
combination to more effectively treat strokes.
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